NASDAQ:GNTA Genenta Science Q4 2025 Earnings Report $0.68 -0.02 (-3.42%) As of 09/21/2026 03:59 PM Eastern ProfileEarnings HistoryForecast Genenta Science EPS ResultsActual EPS-$0.08Consensus EPS -$0.36Beat/MissBeat by +$0.29One Year Ago EPSN/AGenenta Science Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGenenta Science Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Genenta Science Earnings HeadlinesGenenta Science (NASDAQ:GNTA) Trading Down 10.7% - Time to Sell?September 17, 2026 | americanbankingnews.comSòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into OrbitSeptember 15, 2026 | globenewswire.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal. | American Alternative (Ad)GENENTA SCIENCE SPA: Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | finanznachrichten.deGenenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmJuly 23, 2026 | globenewswire.comGENENTA SCIENCE SPA: Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsJuly 22, 2026 | finanznachrichten.deSee More Genenta Science Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genenta Science? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genenta Science and other key companies, straight to your email. Email Address About Genenta ScienceGenenta Science (NASDAQ:GNTA) S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer. The company’s approach is designed to use genetically modified hematopoietic stem cells to deliver therapeutic proteins directly within the tumor microenvironment, with the goal of improving the effectiveness and tolerability of cancer treatment. Genenta’s lead investigational program, Temferon, is an autologous stem-cell-based gene therapy intended to generate immune cells capable of producing interferon-alpha at tumor sites. The company has primarily explored Temferon in glioblastoma and other solid tumors, including settings where localized and sustained delivery of immunomodulatory agents may be beneficial. Temferon is an investigational therapy and has not been approved for commercial use. Founded in Italy, Genenta conducts its research and development activities through operations serving international clinical and biotechnology markets. The company was co-founded by Pierluigi Paracchi, who has served as its chief executive officer. Genenta’s American depositary shares began trading on the Nasdaq under the symbol GNTA in 2021.View Genenta Science ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
